Evidence map›Paper›PMID 39543845›Full record

ArticleActa oncologica (Stockholm, Sweden)2024

Survival outcomes for HER2-low breast cancer: Danish national data.

Michael Sode, Kåre Nielsen, Maj-Britt Jensen, Tobias Berg, Ann Knoop, Bent Ejlertsen, Anne-Vibeke Lænkholm

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta oncologica (Stockholm, Sweden), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Michael SodeDepartment of Surgical Pathology, Zealand University Hospital, Roskilde, Denmark. micsod@yahoo.dk.ORCID 0000-0002-5449-4021
Kåre NielsenDepartment of Surgical Pathology, Zealand University Hospital, Roskilde, Denmark.
Maj-Britt JensenDanish Breast Cancer Group, DBCG, Rigshospitalet, Copenhagen University Hospital, Denmark.
Tobias BergDanish Breast Cancer Group, DBCG, Rigshospitalet, Copenhagen University Hospital, Denmark; Department of Clinical Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark.
Ann KnoopDepartment of Clinical Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark.
Bent EjlertsenDanish Breast Cancer Group, DBCG, Rigshospitalet, Copenhagen University Hospital, Denmark; Department of Clinical Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
Anne-Vibeke LænkholmDepartment of Surgical Pathology, Zealand University Hospital, Roskilde, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeWe investigated the prognosis of breast cancer (BC) with low expression of human epidermal growth factor receptor 2 (HER2), as previous studies have found varying impacts on survival of HER2-low BC compared with HER2 0 BC (HER2 IHC score of 0). HER2-low is defined as a score of 1+ or 2+ in an immunohistochemical (IHC) assay without HER2 gene amplification. MATERIALS AND

methodsPatients with HER2 0 or HER2-low BC from the national Danish Breast Cancer Group database were examined by multivariable survival analysis in a retrospective noninterventional investigation. Patients were grouped as either HER2 0 or HER2-low. The primary endpoint was time to recurrence (TR), and the secondary endpoints were overall survival (OS) and distant recurrence-free interval (DRFI).

results41,610 patients were included (12,981 with HER2 0 BC and 28,629 with HER2-low BC). HER2-low BC was associated with a lower risk of recurrence (hazard ratio [HR]: 0.92, p = 0.03). Regarding secondary endpoints, HER2-low disease was linked to improved overall OS (HR: 0.94, p = 0.02). No statistically significant effect of HER2-low was found for DRFI, along with no differential effect of HER2-low according to estrogen receptor (ER) status.

interpretationHER2-low BC was found to show an improved HR for OS and DRFI compared with HER2 0 BC; however, further studies are need to establish whether it represents a separate biological entity.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesAdultAgedAged, 80 and overBiomarkers, TumorDenmarkFemaleHumansMiddle AgedNeoplasm Recurrence, LocalPrognosisReceptors, EstrogenRetrospective StudiesBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, Estrogen

Identifiers

PMID39543845
PMCPMC11586675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.